The aim of this single-center study was to compare the incidence of viral infections ( cytomegalovirus , Epstein Barr virus , BK virus , and JC virus ) , in 62 de novo kidney transplant patients enrolled in the BENEFIT studies , receiving either belatacept ( n = 42 ) or cyclosporine ( n = 20 ) .